EFFECT OF COMBINED VILDAGLIPTIN AND SACUBITRIL/ VALSARTAN THERAPY ON PORTAL HYPERTENSION IN CIRRHOTIC RATS (AASLD 2026) - Oct 6, 2026 - Abstract #1493; Pres time: Nov 5, 2026; 12:00 PM - 01:00 PM; Location: Convention Center: Poster Hall, Hall DE; "Rats received vildagliptin (DPP-i; 10 mg/kg), sacubitril/ valsartan (ARNI; 30 mg/kg), DPP-i + ARNI, or carvedilol (NSBB; 10 mg/kg). DPP-i and ARNI improved portal hypertension and liver fibrosis and demonstrated additive benefits when combined. This therapeutic strategy may represent a novel treatment option for cirrhosis-associated portal hypertension."
Preclinical • Cardiovascular • Fibrosis • Hepatology • Hypotension • Immunology • Liver Cirrhosis • Portal Hypertension • ACTA2 • CD34 • COL1A1 • CTGF • NOS3 • PACERR • PTGS2 • TGFB1
|
|
Masafumi Oyama1; Kosuke Kaji1; Hitoshi Yoshiji2
|